Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.54 |
| ▸ | PYGM | P11217 | 2/20 | 0.44 |
| ▸ | TYMP | P19971 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642253 | 1.00 | TK2 (0.54) | TK2PYGMTYMPCDK1 | |
| SCHEMBL2338012 | 1.00 | TK2 (0.54) | TK2PYGMTYMPCDK1 | |
| SCHEMBL2344104 | 0.90 | TK2 (0.53) | TK2PYGMTYMPCDK1 | |
| SCHEMBL6516935 | 0.89 | TK2 (0.51) | TK2PYGMTYMPCDK1 | |
| SCHEMBL12642179 | 0.89 | TK2 (0.51) | TK2PYGMTYMPCDK1 | |
| SCHEMBL22992480 | 0.88 | TK2 (0.67) | TK2PYGMTYMP | |
| SCHEMBL20875706 | 0.88 | TK2 (0.67) | TK2PYGMTYMP | |
| SCHEMBL62322 | 0.88 | TK2 (0.67) | TK2PYGMTYMP | |
| SCHEMBL22992424 | 0.88 | TK2 (0.67) | TK2PYGMTYMP | |
| SCHEMBL7182936 | 0.88 | TK2 (0.67) | TK2PYGMTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361923-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100151458-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7695902-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7629321-B2 | Oligoribonucleotides and oligoribonucleosides that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase (double stranded RNAase) | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7432250-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432249-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | COOK PHILLIP D | 2007-10-04 | — | — | US | disclosed |
| EP-0813539-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1621545-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1600506-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20030096286-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030096287-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | IONIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ISIS PHARMACEUTICALS, INC. | 2003-03-13 | — | — | US | disclosed |
| US-20020165189-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6222025-B1 | OLIGONUCLEOTIDES HAVING 2' AND 5 SUBSTITUTED PYRIMIDINE NUCLEOTIDES; INCREASED AFFINITY FOR NUCLEIC ACIDS; INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| US-6166197-A | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6107094-A | IN VITRO MODIFICATION OF TARGET RNA BY CONTACTING SOLUTION OF TARGET AND RIBONUCLEASE PREFERENTIAL FOR DOUBLE-STRANDED RNA WITH OLIGONUCLEOTIDE COMPLEMENTARY TO TARGET AND INCLUDING NUCLEOTIDES MODIFIED TO IMPROVE AFFINITY/SPECIFICITY | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | disclosed |
| US-5861493-A | ALKYLATING WITH ALCOHOL IN PRESENCE OF LEWIS ACID; PREPARING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5760202-A | TREATING 2,2'-ANHYDROPYRIMIDINE NUCLEOSIDE WITH ALCOHOL AND LEWIS ACID | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | TYMS, RRM2, ATIC | TK2 39/4885PYGM 1292/4885TYMP 12/4885 |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ATIC, TYMS, RRM2 | TK2 37/4885PYGM 1120/4885TYMP 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.